Cervical cancer: the most relevant immunological and genetic aspects

[1]  H. Adami,et al.  Cervical cancer and the elusive male factor. , 2002, The New England journal of medicine.

[2]  M. Carrington,et al.  Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  D. Skegg.  Oral contraceptives, parity, and cervical cancer , 2002, The Lancet.

[4]  V. Moreno,et al.  Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study , 2002, The Lancet.

[5]  V. Moreno,et al.  Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study , 2002, The Lancet.

[6]  T. Kawarabayashi,et al.  Local Immune Response in Squamous Cell Carcinoma of the Uterine Cervix , 2001, Gynecologic and Obstetric Investigation.

[7]  S. Wacholder,et al.  HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica , 2001, British Journal of Cancer.

[8]  M. Rudolf,et al.  Cervical cancer vaccines: Emerging concepts and developments , 2001, Journal of cellular physiology.

[9]  M. Mori,et al.  [Recent progress in epidemiologic research of uterine cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  C. Janeway,et al.  Manipulation of the Immune Response , 2001 .

[11]  J. Kovarik,et al.  [Papillomaviruses and human tumors]. , 2000, Casopis lekaru ceskych.

[12]  D. Mukhopadhyay,et al.  Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner , 2000, Oncogene.

[13]  S. Dasgupta.  Immunology of cancer cervix. , 2000, Journal of the Indian Medical Association.

[14]  N. S. Murthy,et al.  Risk factors for pre‐cancerous lesions of the cervix , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[15]  R. Salmaso,et al.  Prognostic value of bcl-2, p53 and Ki-67 in invasive squamous carcinoma of the uterine cervix. , 2000, European journal of gynaecological oncology.

[16]  A. Zwinderman,et al.  Presence of an eosinophilic infiltrate in cervical squamous carcinoma results from a type 2 immune response. , 1999, Gynecologic oncology.

[17]  M. Lehtinen,et al.  Low levels of serum vitamins A and E in blood and subsequent risk for cervical cancer: interaction with HPV seropositivity. , 1999, Nutrition and cancer.

[18]  G. Fleuren,et al.  Immunotherapeutic strategies for cervical squamous carcinoma. , 1999, Hematology/oncology clinics of North America.

[19]  M. Clerici,et al.  Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. , 1998, Journal of the National Cancer Institute.

[20]  E. Tartour,et al.  Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. , 1998, Journal of the National Cancer Institute.

[21]  J. Berzofsky,et al.  Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  B. Sheu,et al.  Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. , 1997, Human immunology.

[23]  H. Hollema,et al.  Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies , 1997, Cancer Immunology, Immunotherapy.

[24]  S. Stacey,et al.  Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. , 1997, British Journal of Cancer.

[25]  F. X. Bosch,et al.  Human papillomavirus and other risk factors for cervical cancer. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[26]  Fiona Macdonald,et al.  Molecular Biology of Cancer , 1996 .

[27]  T. Whiteside,et al.  Role of human natural killer cells in health and disease , 1994, Clinical and diagnostic laboratory immunology.